磷脂酰肌醇3-激酶抑制剂在复发难治外周T细胞淋巴瘤中的研究进展  

Research progress of phosphatidylinositol 3-kinase inhibitors in relapsed refractory peripheral T-cell lymphoma

作　　者：潘芝娟 张轶群 郭志萍 Pan Zhijuan;Zhang Yiqun;Guo Zhiping(Department of Hematology,Peking University First Hospital Taiyuan Branch&Taiyuan Central Hospital of Shanxi Medical University,Taiyuan 030006,China)

机构地区：[1]北京大学第一医院太原医院,太原市中心医院血液科,太原030006

出　　处：《中国综合临床》2024年第6期422-426,共5页Clinical Medicine of China

摘　　要：外周T细胞淋巴瘤(peripheral T-cell lymphoma, PTCL)是我国较为常见的一种非霍奇金淋巴瘤亚型, 临床多具有较高侵袭性, 疾病进展迅速, 目前治疗效果差, 总体预后不良, 复发难治患者尤为如此。近年来, 磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase, PI3K)抑制剂的研究发展迅速, 可以有效改善复发难治PTCL患者的预后。现综述近年来PI3K抑制剂治疗复发难治PTCL的治疗机制、有效性及安全性。Peripheral T-cell lymphoma(PTCL)is a relatively common subtype of non-Hodgkin lymphomain in China.PTCL is clinically highly aggressive,and it progresses rapidly.The current treatment methods are ineffective and the overall prognosis is poor,especially in patients with relapsed and/or refractory.In recent years,the treatment of phosphatidylinositol 3-kinase(PI3K)inhibitors has developed rapidly,which can effectively improve the prognosis of patients with relapsed and/or refractory PTCL.This article reviews the therapeutic mechanism,effectiveness and safety of PI3K inhibitors in the treatment of relapsed and/or refractory PTCL.

关 键 词：淋巴瘤 复发难治 磷脂酰肌醇3-激酶 外周T细胞 

分 类 号：R733.1[医药卫生—肿瘤]